Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 53

Inclusion Criteria

Male or female patients with confirmed diagnosis of advanced, non-resectable and / or metastatic solid tumours, of types historically known to express EGFR and/or HER2, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment preferably patients with breast, colorectal or prostate cancer
Age 18 years or older
Life expectancy of at least three (3) months
Written informed consent that is consistent with International Conference on Harmonization - Good Clinical Practice guidelines
Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2
Patients completely recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies to CTC <= Grade 1
Patients must be recovered from previous surgery

The 12 additional patients recruited at the MTD must also meet the following criteria:

Measurable tumour deposits (RECIST) by one or more techniques (X-ray, CT, MRI) and/or recognized tumour markers such as prostate-specific antigen prostate cancer) or cancer antigen 125 (Ovarian cancer)

Exclusion Criteria

Active infectious disease
Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea
Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least eight (8) weeks, no history of cerebral edema or bleeding in the past eight (8) weeks and no requirement for steroids or anti-epileptic therapy
Cardiac left ventricular function with resting ejection fraction CTC >= Grade 1
Absolute neutrophil count (ANC) less than 1500 / mm3
Platelet count less than 100 000 / mm3
Bilirubin greater than 1.5 mg /dl (>26 μmol /L, Système Internationale (SI) unit equivalent)
Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
Serum creatinine greater than 1.5 mg / dl (>132 μmol / L, SI unit equivalent)
Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
Pregnancy or breast-feeding
Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (excluding Luteinizing Hormone-Releasing Hormone agonists, or other hormones taken for breast cancer, or bisphosphonates), or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study
Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before start of therapy or concomitantly with this study (8 weeks for trastuzumab)
Patients unable to comply with the protocol
Active alcohol or drug abuse

A patient may be eligible for re-treatment after the previous course is finished. A patient will not be eligible if any of the following conditions are met.

Patients with clinical signs of disease progression or if latest X-ray, CT or MRI reveals Progressive Disease
Cardiac left ventricular function CTC >= Grade 2 at any time during the previous course
Patients fulfilling any of the Exclusion Criteria listed before as determined before treatment on Day 28, R5 of the previous course
Patient not recovered from any dose-limiting toxicity 14 days after the last administration of BIBW 2992 in the previous course. Recovery is defined as return to baseline level or CTC Grade 1, whichever is higher

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BIBW 2992	BIBW 2992	dose escalation
BIBW 2992, fasted	BIBW 2992	food effect part: maximum tolerated dose of BIBW 2992
BIBW 2992, fed	BIBW 2992	food effect part: maximum tolerated dose of BIBW 2992

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD) of BIBW 2992	up to 24 weeks
Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 3) associated with increasing doses of BIBW 2992	up to 28 weeks

Secondary Outcome Measures

Name	Time	Method
apparent clearance (CL/F(ss))	up to 648 hours after first drug administration, pre-dose on day 15 and 28
apparent volume of distribution during the terminal phase (Vz/F(ss))	up to 648 hours after first drug administration, pre-dose on day 15 and 28
mean residence time after oral administration (MRTpo(ss))	up to 648 hours after first drug administration, pre-dose on day 15 and 28
Accumulation ratio between Day 1 and Day 27 with respect to Cmax (RA1) and AUC (RA2)	up to 648 hours after first drug administration, pre-dose on day 15 and 28
Modulation of biomarker (EGFR, p-EGFR, p-MAPK, p-Akt, Ki 67, p-27KIP1) in skin biopsies	Baseline and day 28 of the first treatment period
Modulation of biomarker (EGFR, p-EGFR, HER2 (Class I Tyrosine Kinase Receptor), p-MAPK (mitogen-activated protein kinase), p-Akt, Ki 67, p-27KIP1) in tumour biopsies in six or more patients treated at the MTD	Baseline and day 28 of the first treatment period
Objective tumour response	up to 25 weeks
Correlation of EGFR, HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumour biopsies, or excisions obtained prior to this study, with objective tumour responses	up to 25 weeks
Area under the plasma concentration-time curve (AUC) for several time points	up to 648 hours after first drug administration, pre-dose on day 15 and 28
Percentage of AUC0-∞ that is obtained by extrapolation (%AUCtz-∞)	up to 648 hours after first drug administration, pre-dose on day 15 and 28
predose plasma concentration	predose on days 8, 15, 22 and 27
Plasma concentration	24 hours after drug administration on the first (C24,1) and the Day 27 dose (C24,27)
Maximum measured plasma concentration (Cmax) for several time points	up to 648 hours after first drug administration, pre-dose on day 15 and 28
Time from dosing to the maximum plasma concentration (tmax) for several time points	up to 648 hours after first drug administration, pre-dose on day 15 and 28
terminal half-life (t1/2(ss))	up to 648 hours after first drug administration, pre-dose on day 15 and 28

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Recruitment & Eligibility

Study & Design

Instant Trial Alerts

Instant Trial Alerts